Patient safety remains a priority of the NICTN. At the outset of the local COVID-19 crisis NICTN suspended recruitment to the majority of clinical trials and other research studies. In alignment with national guidance, NICTN is currently working to re-activate recruitment to studies, where this is feasible and safe. Anyone who wishes to consider participation in a cancer clinical trial should discuss this with their doctor.
